​

Protara Therapeutics (TARA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

TARA Stock Forecast

Protara Therapeutics (TARA) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $12.00, with a high of $12.00 and a low of $12.00. This represents a 135.76% increase from the last price of $5.09.

- $3 $6 $9 $12 $15 High: $12 Avg: $12 Low: $12 Last Closed Price: $5.09

TARA Stock Rating

Protara Therapeutics stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 5 Strong Sell Sell Hold Buy Strong Buy

TARA Price Target Upside V Benchmarks

TypeNameUpside
StockProtara Therapeutics135.76%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$12.00
Last Closing Price$5.09$5.09$5.09
Upside/Downside--135.76%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2515---6
Sep, 2515---6
Aug, 2525---7
Jul, 2525---7
Jun, 2525---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 16, 2025George FarmerScotiabank$12.00$4.00200.00%135.76%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 16, 2025ScotiabankOutperforminitialise
Dec 05, 2024Cowen & Co.BuyBuyhold
Aug 06, 2024Cowen & Co.BuyBuyhold
Apr 05, 2024Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.57$-2.17----
Avg Forecast$-3.57$-3.32$-3.40$-2.18$-2.33$-1.34
High Forecast$-3.17$-2.23$-1.79$-1.42$-1.69$-1.34
Low Forecast$-3.84$-5.93$-6.90$-2.93$-2.96$-1.34
Surprise %--34.64%----

Revenue Forecast

$0 $14M $28M $42M $56M $70M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast-$3.22M$24.87M$22.30M$6.35M$66.50M
High Forecast-$3.22M$24.87M$22.30M$6.35M$66.50M
Low Forecast-$3.22M$24.87M$22.30M$6.35M$66.50M
Surprise %------

Net Income Forecast

$-80M $-67M $-54M $-41M $-28M $-15M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-40.42M$-44.60M----
Avg Forecast$-40.42M$-42.05M$-55.06M$-24.65M$-26.35M$-15.18M
High Forecast$-35.90M$-25.26M$-20.23M$-16.09M$-19.15M$-15.18M
Low Forecast$-43.56M$-67.25M$-78.16M$-33.20M$-33.54M$-15.18M
Surprise %-6.06%----

TARA Forecast FAQ

Is Protara Therapeutics stock a buy?

Protara Therapeutics stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Protara Therapeutics is a favorable investment for most analysts.

What is Protara Therapeutics's price target?

Protara Therapeutics's price target, set by 5 Wall Street analysts, averages $12 over the next 12 months. The price target range spans from $12 at the low end to $12 at the high end, suggesting a potential 135.76% change from the previous closing price of $5.09.

How does Protara Therapeutics stock forecast compare to its benchmarks?

Protara Therapeutics's stock forecast shows a 135.76% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Protara Therapeutics over the past three months?

  • October 2025: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Protara Therapeutics’s EPS forecast?

Protara Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.4, marking a 56.68% increase from the reported $-2.17 in 2024. Estimates for the following years are $-2.18 in 2026, $-2.33 in 2027, and $-1.34 in 2028.

What is Protara Therapeutics’s revenue forecast?

Protara Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $24.87M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $22.3M, followed by $6.35M for 2027, and $66.5M for 2028.

What is Protara Therapeutics’s net income forecast?

Protara Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-55.057M, representing an 23.46% increase from the reported $-44.596M in 2024. Projections indicate $-24.646M in 2026, $-26.345M in 2027, and $-15.184M in 2028.